For the Inventor, By the Inventor

Enter assignee name

Morris Plains, NJ, United States of America

Warner Lambert LLC

USPTO Granted Patents = 22

% Expired Patents = 31.8

Trademarks = 1

Forward Citations = 247

Loading Chart...

Loading Chart...

49 inventors (with patents filed for the assignee):

Patrick Bernardelli (3 out of 9 patents)

Charles Andrianjara (2 out of 3 patents)

Remi Lavalette (2 out of 2 patents)

4. Claude Forsey Purchase, Jr (2 out of 16 patents)

5. Gerald Paul Schielke (2 out of 5 patents)

6. Lary Craswell Walker (2 out of 5 patents)

7. Andrew David White (2 out of 31 patents)

8. Bruce D Roth (2 out of 77 patents)

9. James S Kaltenbronn (2 out of 32 patents)

10. Leonard Doub (2 out of 7 patents)

11. Theodore H Haskell (2 out of 17 patents)

12. Brian Desmond Palmer (1 out of 19 patents)

13. Roger Schofield Newton (1 out of 11 patents)

14. Jonathan Miller (1 out of 37 patents)

15. Gordon William Rewcastle (1 out of 33 patents)

22 patents: Sort by Forward Citations

1. 8383667 - Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium (2013-02-26),

2. 7122565 - Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors (2006-10-17),

3. 6962912 - Substituted pyrazolo[4,3-e]diazepines, pharmaceutical compositions containing them, use as medicinal products and processes for preparing them (2005-11-08),

4. 6878821 - Modifying chemoselectivity during oxidation of nitrogen compounds (2005-04-12),

5. 6828315 - 1-Amino triazoloc4,3-a&excl; quinazoline-5-ones and/or -5-thiones inhibiting phosphodiesterase IV (2004-12-07),

6. 6787554 - Triazolo[4,3-a]pyrido[2,3-d]pyrimidin-5-one derivatives (2004-09-07),

7. 6747035 - 1-alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors (2004-06-08),

8. 6689881 - Method for preparing substituted [1,4]diazepino[6,7,1-hi]indol-4-ones (2004-02-10),

9. 6395930 - Quenching reagents for solution phase synthesis (2002-05-28),

10. 6265432 - Flourine-substituted biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases (2001-07-24),

11. 6251919 - Heterocyclic substituted aniline calcium channel blockers (2001-06-26),

12. 6169103 - Fluorine-substituted biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases (2001-01-02),

13. 5877022 - Ribozymes targeted to APO(a) RNA (1999-03-02),

14. 5464861 - 2-thioindoles (selenoindoles) and related disulfides (selenides) which (1995-11-07),

15. 4738981 - Substituted trans-1,2-diaminocyclohexyl amide compounds (1988-04-19),

Warner Lambert LLC, headquartered in Morris Plains, NJ, is a prominent player in the pharmaceutical industry, focusing on the development and manufacturing of innovative healthcare products. The company specializes in a diverse range of therapeutic areas, including cardiovascular health, pain management, and infectious diseases. With a commitment to research and development, Warner Lambert aims to enhance patient outcomes through advanced medical solutions and effective treatments, contributing significantly to global health initiatives.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

22 Patents

#6 in Morris Plains, NJ

#578 in New Jersey

#15,012 in US

#28,724 in the World

Morris Plains, NJ, United States of America

Warner Lambert LLC

Forward Citations = 247

49 inventors:

Patrick Bernardelli (3 out of 9 patents)

Charles Andrianjara (2 out of 3 patents)

Remi Lavalette (2 out of 2 patents)

4. Claude Forsey Purchase, Jr (2 out of 16 patents)

5. Gerald Paul Schielke (2 out of 5 patents)

Please report any incorrect information to [email protected]

Loading…